Profile data is unavailable for this security.
About the company
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).
- Revenue in USD (TTM)190.86m
- Net income in USD-16.39m
- Incorporated2002
- Employees203.00
- LocationVanda Pharmaceuticals IncSUITE 300E, 2200 PENNSYLVANIA AVE NWWASHINGTON 20037United StatesUSA
- Phone+1 (202) 734-3400
- Fax+1 (202) 296-1450
- Websitehttps://www.vandapharma.com/
More ▼
Mergers & acquisitions
| Acquired company | VNDA:NMQ since announced | Transaction value |
|---|---|---|
| Actelion Pharmaceuticals Ltd-PONVORY | 33.66% | 100.00m |
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADC Therapeutics SA | 70.72m | -212.15m | 288.14m | 273.00 | -- | -- | -- | 4.07 | -2.40 | -2.40 | 0.7742 | -1.78 | 0.1733 | 0.2987 | 3.13 | 259,036.60 | -51.13 | -48.41 | -62.27 | -55.63 | 91.81 | -- | -295.00 | -308.62 | 4.68 | -3.92 | 1.65 | -- | -66.86 | 127.56 | -52.78 | -- | 5.42 | -- |
| Biomea Fusion Inc | 0.00 | -144.01m | 291.00m | 107.00 | -- | 3.83 | -- | -- | -4.00 | -4.00 | 0.00 | 2.10 | 0.00 | -- | -- | 0.00 | -85.85 | -- | -98.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.29 | -- | -- | -- |
| Fate Therapeutics Inc | 12.32m | -175.72m | 291.53m | 181.00 | -- | 0.7342 | -- | 23.67 | -1.71 | -1.71 | 0.1185 | 3.49 | 0.0221 | -- | 6.35 | 68,049.73 | -31.56 | -31.82 | -33.99 | -36.05 | -- | -- | -1,426.67 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
| Zura Bio Ltd | 0.00 | -42.62m | 301.01m | 14.00 | -- | 2.01 | -- | -- | -0.5807 | -0.5807 | 0.00 | 2.34 | 0.00 | -- | -- | 0.00 | -32.18 | -- | -43.31 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2,050.99 | -- | -- | -- |
| Tscan Therapeutics Inc | 12.20m | -104.41m | 301.95m | 175.00 | -- | 1.18 | -- | 24.75 | -1.05 | -1.05 | 0.1225 | 4.82 | 0.0353 | -- | -- | 79,220.78 | -30.19 | -- | -33.78 | -- | -- | -- | -855.84 | -- | -- | -- | 0.1066 | -- | 55.52 | -- | -34.73 | -- | -- | -- |
| Nautilus Biotechnology Inc | 0.00 | -70.21m | 303.86m | 161.00 | -- | 1.36 | -- | -- | -0.561 | -0.561 | 0.00 | 1.78 | 0.00 | -- | -- | 0.00 | -24.29 | -- | -25.05 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.93 | -- | -- | -- |
| Ocugen Inc | 8.19m | -45.87m | 308.01m | 65.00 | -- | 16.27 | -- | 37.60 | -0.1785 | -0.1785 | 0.0319 | 0.0658 | 0.1265 | -- | -- | 126,015.40 | -78.54 | -83.56 | -103.70 | -97.79 | -- | -- | -620.91 | -2,921.94 | -- | -- | 0.1445 | -- | 142.60 | -- | 27.33 | -- | 39.08 | -- |
| Mersana Therapeutics Inc | 29.94m | -104.77m | 310.37m | 123.00 | -- | 36.83 | -- | 10.37 | -0.8648 | -0.8648 | 0.2469 | 0.0687 | 0.1222 | -- | 38.14 | 243,390.30 | -42.75 | -61.68 | -59.36 | -81.35 | -- | -- | -349.98 | -622.19 | -- | -- | 0.7508 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
| Vanda Pharmaceuticals Inc. | 190.86m | -16.39m | 311.27m | 203.00 | -- | 0.5753 | -- | 1.63 | -0.2824 | -0.2824 | 3.29 | 9.28 | 0.2967 | 9.30 | 5.30 | 940,187.20 | -2.55 | 6.61 | -2.95 | 7.62 | 93.62 | 90.55 | -8.59 | 15.18 | 4.84 | -- | 0.00 | 0.00 | -24.27 | -0.0496 | -60.02 | -36.96 | -56.77 | -- |
| AC Immune SA | 17.59m | -68.72m | 313.64m | 133.00 | -- | 2.24 | -- | 17.83 | -0.7289 | -0.7289 | 0.19 | 1.41 | 0.0787 | -- | 28.76 | 132,255.70 | -30.73 | -18.25 | -42.90 | -19.52 | -- | -- | -390.68 | -148.29 | -- | -128.01 | 0.0255 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
| AVITA Medical Inc | 60.04m | -57.32m | 317.07m | 207.00 | -- | 26.16 | -- | 5.28 | -2.23 | -2.23 | 2.33 | 0.4664 | 0.7409 | 1.53 | 7.30 | 290,048.30 | -70.74 | -- | -86.14 | -- | 86.46 | -- | -95.47 | -- | 3.37 | -11.27 | 0.7768 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
| Artiva Biotherapeutics Inc | -100.00bn | -100.00bn | 324.96m | 82.00 | -- | -- | -- | -- | -- | -- | -- | 1.09 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0087 | -- | 579.21 | -- | 51.15 | -- | -- | -- |
| Aldeyra Therapeutics Inc | 0.00 | -44.80m | 326.22m | 10.00 | -- | 3.84 | -- | -- | -0.7538 | -0.7538 | 0.00 | 1.43 | 0.00 | -- | -- | 0.00 | -33.86 | -36.79 | -39.67 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1522 | -- | -- | -- | 39.47 | -- | -- | -- |
| Codexis Inc | 64.45m | -62.09m | 330.39m | 174.00 | -- | 4.50 | -- | 5.13 | -0.878 | -0.878 | 0.9149 | 0.902 | 0.4259 | 7.03 | 3.62 | 370,379.30 | -41.03 | -17.13 | -54.21 | -20.23 | 75.96 | 77.29 | -96.35 | -37.04 | 3.15 | -- | 0.2806 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
| Taysha Gene Therapies Inc | 12.87m | -114.34m | 334.06m | 52.00 | -- | 3.02 | -- | 25.95 | -0.8987 | -0.8987 | 0.0643 | 0.5406 | 0.0913 | -- | -- | 247,557.70 | -81.11 | -- | -116.01 | -- | -- | -- | -888.18 | -- | -- | -- | 0.2598 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
Data as of Nov 12 2024. Currency figures normalised to Vanda Pharmaceuticals Inc's reporting currency: US Dollar USD
42.73%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Jun 2024 | 5.53m | 9.49% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 4.11m | 7.06% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 3.37m | 5.78% |
| Tang Capital Management LLCas of 30 Jun 2024 | 2.15m | 3.69% |
| Dimensional Fund Advisors LPas of 30 Sep 2024 | 2.13m | 3.66% |
| Acadian Asset Management LLCas of 30 Jun 2024 | 1.98m | 3.40% |
| Nantahala Capital Management LLCas of 30 Jun 2024 | 1.59m | 2.73% |
| Jacobs Levy Equity Management, Inc.as of 30 Jun 2024 | 1.49m | 2.55% |
| Geode Capital Management LLCas of 30 Jun 2024 | 1.33m | 2.28% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 1.21m | 2.08% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
